CHMP calls for Novartis drug to be used to cut risk of postoperative DMO
This article was originally published in Scrip
Executive Summary
Members of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) are recommending that Nevanac nepafenac from Alcon Laboratories, now owned by Novartis, should be used to reduce the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. The non-steroidal anti-inflammatory prodrug of amfenac was approved to treat and prevent postoperative pain and inflammation associated with cataract surgery in the US in 2005 and the European Union in 2007.